My background has primarily focused on the developmental and reproductive toxicities associated with environmental pollutants in aquatic organisms. During my time at the University of Mississippi, I extended my expertise by developing a mechanism for which we can study the therapeutic potential of cannabinoids for the treatment of rare forms of epilepsy. More importantly, we managed to forge ahead in the unknown field of cannabinoid toxicology and were one of the first labs to publish adverse developmental endpoints for cannabidiol in zebrafish.
Dr. Ashish Dhir is an Associate Project Scientist at the University of California, Davis with 14 years of experience in neurology research. At the CounterACT Center, Dr. Dhir is conducting tests of antiseizure agents in models of acute seizures (status epilepticus) and lethality produced by chemical threat agents of the organophosphate cholinesterase-inhibiting type, including DFP. He is also involved in the development of spontaneous recurrent seizures through long-term monitoring following DFP-induced status epilepticus.
My interest in biomedical research began with my undergraduate training in environmental and molecular toxicology. I have since been trained in neurotoxicology and neuropharmacology as a doctoral student working under Dr. Pamela Lein. The CounterACT program has allowed me to combine my passions for toxicology, public health, and national security by applying my knowledge of toxicology to counterterrorism research against chemical weapons.
I am originally from Baltimore, MD and got my B.S. in both Biochemistry and Toxicology from Penn State University. Currently, I am a Pharmacology and Toxicology PhD student working with Dr. Pamela Lein within the CounterACT Center of Excellence.
Danielle J. Harvey, PhD, is an Associate Professor in the Division of Biostatistics, Department of Public Health Sciences, School of Medicine, at UC Davis. Her research primarily focuses on the statistical analysis of neuroimaging data. For the past fifteen years, she has worked in the area of Alzheimer’s disease, with particular emphasis on the use of neuroimaging to identify markers of disease progression.
Brad Hobson is a PhD candidate in the Pharmacology and Toxicology graduate group working in the lab of Dr. Pamela Lein. His research within the CounterACT program focuses on investigating the long term neurological consequences of acute organophosphate (OP) intoxication using in vivo imaging.